A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014
Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014
Sing-a-Lung: Group singing as training modality in pulmonary rehabilitation for patients with Chronic Obstructive Pulmonary Disease (COPD): A multicenter, cluster-randomised, non-inferiority controlled trial Source: Virtual Congress 2020 – Best abstracts in the field of pulmonary rehabilitation Year: 2020
PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014
Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014
Interim analysis of nintedanib in an open-label extension of the INPULSIS® trials (INPULSIS®-ON) Source: International Congress 2015 – Treatment of IPF Year: 2015
How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study Source: International Congress 2014 – Sarcoidosis Year: 2014
A double-blind, randomized, sham-controlled study of Targeted Lung Denervation in patients with moderate to severe COPD : AIRFLOW-2 One Year Outcomes Source: International Congress 2019 – Interventional pulmonology: a mixture of spices Year: 2019
Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007
Inhaled mannitol for non-cystic fibrosis bronchiectasis - results of a 12 month, multi-centre, double-blind, controlled study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019
Comparison of Interferon gamma-1b (IFN-γ)and colcicine in the treatment of Idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomised study Source: Eur Respir J 2002; 20: Suppl. 38, 599s Year: 2002
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
LATE-BREAKING ABSTRACT: Simtuzumab in idiopathic pulmonary fibrosis: Results of a randomized clinical trial Source: International Congress 2016 – IPF treatment I Year: 2016
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Source: Eur Respir J 2013; 42: 1622-1632 Year: 2013
Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016
Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014
LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study. Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Randomized controlled trial of abituzumab in systemic sclerosis-associated interstitial lung disease Source: International Congress 2017 – New ideas for the management of chronic lung diseases Year: 2017